Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex Dose-Ranging in Dravet Syndrome (Part A)
NCT02091206Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cannabidiol in Dravet syndrome, sponsored by Jazz Pharmaceuticals plc. Started Oct 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT02091206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091206.